title: Therapeutic challenges in advanced renal cell carcinoma.
abstract: The therapeutic landscape of advanced renal cell carcinoma has grown increasingly more complex with the recent approval of several molecularly targeted agents. While researchers focus on developing predictive algorithms and identifying novel therapeutic targets and agents, clinical practitioners continue to face many practical challenges when determining therapeutic strategies for individual patients. This review will discuss several of these challenges including patient selection strategies, sequential therapy, optimal dose and schedule of various drugs, and therapeutic options for patients with nonclear-cell renal cell carcinoma.
authors: Division of Hematology & Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, MASCO 4th Floor, Boston, MA 02215, USA; Tel.: +1 617 632 9250; ;  dcho1@bidmc.harvard.edu.
authors: Daniel C
authors: DC
authors: Cho
references: J Urol. 2007 Nov;178(5):1883-7
references: 17868732
references: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references: 20100962
references: J Clin Oncol. 2008 Aug 1;26(22):3743-8
references: 18669461
references: Lancet Oncol. 2009 Aug;10(8):757-63
references: 19615940
references: J Clin Oncol. 2009 Sep 20;27(27):4462-8
references: 19652060
references: Clin Cancer Res. 2011 Jun 1;17(11):3841-9
references: 21531811
references: Cancer. 2010 Sep 15;116(18):4256-65
references: 20549832
references: Urology. 2010 Aug;76(2):430-4
references: 20223508
references: Eur Urol. 2012 Dec;62(6):1013-9
references: 22771265
references: Cancer. 2010 Dec 1;116(23):5400-6
references: 21105118
references: J Clin Oncol. 2012 Apr 20;30(12):1371-7
references: 22430274
references: J Clin Oncol. 2004 Mar 1;22(5):909-18
references: 14990647
references: Oncology. 2012;82(6):333-40
references: 22677881
references: Lancet. 2007 Dec 22;370(9605):2103-11
references: 18156031
references: J Immunother. 2009 Feb-Mar;32(2):181-5
references: 19238017
references: Clin Cancer Res. 2011 Aug 15;17(16):5443-50
references: 21828239
references: Cancer. 2009 Jan 1;115(1):61-7
references: 19051290
references: N Engl J Med. 2007 Jan 11;356(2):115-24
references: 17215529
references: Cancer Chemother Pharmacol. 2010 Jul;66(2):357-71
references: 19967539
references: Cancer. 2010 Mar 1;116(5):1272-80
references: 20082451
references: J Natl Compr Canc Netw. 2009 Jun;7(6):618-30
references: 19555584
references: Med Oncol. 2009;26(2):202-9
references: 19229667
references: Lancet. 2008 Aug 9;372(9637):449-56
references: 18653228
references: J Clin Oncol. 2010 May 1;28(13):2137-43
references: 20368558
references: N Engl J Med. 2007 May 31;356(22):2271-81
references: 17538086
references: Lancet Oncol. 2007 Nov;8(11):975-84
references: 17959415
references: Lancet. 2011 Dec 3;378(9807):1931-9
references: 22056247
references: N Engl J Med. 2007 Jan 11;356(2):125-34
references: 17215530